BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 19946779)

  • 1. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
    Seelaar H; Klijnsma KY; de Koning I; van der Lugt A; Chiu WZ; Azmani A; Rozemuller AJ; van Swieten JC
    J Neurol; 2010 May; 257(5):747-53. PubMed ID: 19946779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
    Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
    Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.
    Urwin H; Josephs KA; Rohrer JD; Mackenzie IR; Neumann M; Authier A; Seelaar H; Van Swieten JC; Brown JM; Johannsen P; Nielsen JE; Holm IE; ; Dickson DW; Rademakers R; Graff-Radford NR; Parisi JE; Petersen RC; Hatanpaa KJ; White CL; Weiner MF; Geser F; Van Deerlin VM; Trojanowski JQ; Miller BL; Seeley WW; van der Zee J; Kumar-Singh S; Engelborghs S; De Deyn PP; Van Broeckhoven C; Bigio EH; Deng HX; Halliday GM; Kril JJ; Munoz DG; Mann DM; Pickering-Brown SM; Doodeman V; Adamson G; Ghazi-Noori S; Fisher EM; Holton JL; Revesz T; Rossor MN; Collinge J; Mead S; Isaacs AM
    Acta Neuropathol; 2010 Jul; 120(1):33-41. PubMed ID: 20490813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS.
    Josephs KA; Whitwell JL; Parisi JE; Petersen RC; Boeve BF; Jack CR; Dickson DW
    Eur J Neurol; 2010 Jul; 17(7):969-75. PubMed ID: 20236174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration.
    Kawakami I; Kobayashi Z; Arai T; Yokota O; Nonaka T; Aoki N; Niizato K; Oshima K; Higashi S; Katsuse O; Hosokawa M; Hasegawa M; Akiyama H
    Acta Neuropathol Commun; 2016 Apr; 4():36. PubMed ID: 27044537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FUS pathology in basophilic inclusion body disease.
    Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
    Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.
    Kobayashi Z; Arai T; Kawakami I; Yokota O; Hosokawa M; Oshima K; Niizato K; Shiraishi A; Akiyama H; Mizusawa H
    Psychogeriatrics; 2018 Jul; 18(4):307-312. PubMed ID: 30133939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.
    A Armstrong R
    Folia Neuropathol; 2017; 55(3):185-192. PubMed ID: 28984110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
    Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
    Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological correlations in behavioural variant frontotemporal dementia.
    Perry DC; Brown JA; Possin KL; Datta S; Trujillo A; Radke A; Karydas A; Kornak J; Sias AC; Rabinovici GD; Gorno-Tempini ML; Boxer AL; De May M; Rankin KP; Sturm VE; Lee SE; Matthews BR; Kao AW; Vossel KA; Tartaglia MC; Miller ZA; Seo SW; Sidhu M; Gaus SE; Nana AL; Vargas JNS; Hwang JL; Ossenkoppele R; Brown AB; Huang EJ; Coppola G; Rosen HJ; Geschwind D; Trojanowski JQ; Grinberg LT; Kramer JH; Miller BL; Seeley WW
    Brain; 2017 Dec; 140(12):3329-3345. PubMed ID: 29053860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions.
    Josephs KA; Lin WL; Ahmed Z; Stroh DA; Graff-Radford NR; Dickson DW
    Acta Neuropathol; 2008 Aug; 116(2):159-67. PubMed ID: 18553091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological features of FTLD-FUS in a Japanese population: analyses of nine cases.
    Kobayashi Z; Kawakami I; Arai T; Yokota O; Tsuchiya K; Kondo H; Shimomura Y; Haga C; Aoki N; Hasegawa M; Hosokawa M; Oshima K; Niizato K; Ishizu H; Terada S; Onaya M; Ikeda M; Oyanagi K; Nakano I; Murayama S; Akiyama H; Mizusawa H
    J Neurol Sci; 2013 Dec; 335(1-2):89-95. PubMed ID: 24050818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitin immunohistochemistry of frontotemporal lobar degeneration differentiates cases with and without motor neuron disease.
    Katsuse O; Dickson DW
    Alzheimer Dis Assoc Disord; 2005; 19 Suppl 1():S37-43. PubMed ID: 16317257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Argyrophilic Grain Pathology in Frontotemporal Lobar Degeneration: Demographic, Clinical, Neuropathological, and Genetic Features.
    Gil MJ; Manzano MS; Cuadrado ML; Fernández C; Góméz E; Matesanz C; Calero M; Rábano A
    J Alzheimers Dis; 2018; 63(3):1109-1117. PubMed ID: 29758948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.
    Davidson YS; Robinson AC; Hu Q; Mishra M; Baborie A; Jaros E; Perry RH; Cairns NJ; Richardson A; Gerhard A; Neary D; Snowden JS; Bigio EH; Mann DM
    Neuropathol Appl Neurobiol; 2013 Feb; 39(2):157-65. PubMed ID: 22497712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies.
    Koga S; Murakami A; Soto-Beasley AI; Walton RL; Baker MC; Castanedes-Casey M; Josephs KA; Ross OA; Dickson DW
    Acta Neuropathol Commun; 2023 Jul; 11(1):109. PubMed ID: 37415197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An autopsy case of frontotemporal lobar degeneration with the appearance of fused in sarcoma inclusions (basophilic inclusion body disease) clinically presenting corticobasal syndrome.
    Matsumoto A; Suzuki H; Fukatsu R; Shimizu H; Suzuki Y; Hisanaga K
    Neuropathology; 2016 Feb; 36(1):77-87. PubMed ID: 26227957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new subtype of frontotemporal lobar degeneration with FUS pathology.
    Neumann M; Rademakers R; Roeber S; Baker M; Kretzschmar HA; Mackenzie IR
    Brain; 2009 Nov; 132(Pt 11):2922-31. PubMed ID: 19674978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS.
    Gittings LM; Foti SC; Benson BC; Gami-Patel P; Isaacs AM; Lashley T
    Acta Neuropathol Commun; 2019 Feb; 7(1):18. PubMed ID: 30755280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
    Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
    J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.